Kane Biotech Inc. (KNBIF)

Market Cap	10.59M
Revenue (ttm)	1.49M
Net Income (ttm)	4.14M
Shares Out	n/a
EPS (ttm)	0.03
PE Ratio	2.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,000
Average Volume	13,965
Open	0.0667
Previous Close	0.0667
Day's Range	0.0667 - 0.0667
52-Week Range	0.0621 - 0.1210
Beta	0.25
RSI	42.87
Earnings Date	May 22, 2025

About Kane Biotech

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: KNBIF

Financial Performance

In 2023, Kane Biotech's revenue was 148,980, a decrease of -4.95% compared to the previous year's 156,733. Losses were -5.03 million, 29.4% more than in 2022.

Financial numbers in CAD